Unrecognized Condition: Mature B or T-cell Neoplasm Clinical Trial
Official title:
Randomized Trial of Cyclosporine + CAMPATH-1H (ALEMTUZUMAB) vs. Cyclosporine + METHOTREXATE in Patients Diagnosed With Mature B-cell Neoplasms - Chronic Lymphocytic Leukemia and Low-grade Lymphomas - Receiving Allogeneic Hematopoietic Stem Cell Transplantation With Nonmyeloablative Conditioning Regimen
| Verified date | December 2017 |
| Source | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The primary aim of the study was to compare the efficacy of the procedure in terms of
event-free survival between patients receiving cyclosporine (CsA) plus either alemtuzumab
(CAMPATH-1H ) or methotrexate (MTX) after matched related donor allo-reduced intensity
conditioning. Secondary aims were: 1. To compare the incidence of infections and
transplant-related mortality between the two arms; 2. to compare the incidence of acute and
chronic GVHD 3. to evaluate hematologic and immunologic reconstitution and evolution of
chimerism and residual disease.
Patients were randomly assigned to received cyclosporine plus alemtuzumab or cyclosporine
plus MTX and were stratified according to diagnosis: Chronic lymphocytic leukemia or Low
grade- non-Hodgkin's lymphoma.
All patients received the same reduced-intensity conditioning (RIC) scheme based on
fludarabine 150mg/m2 (30 mg/m2/day everyday from -8 to -4) plus melphalan 140mg/m2 (70
mg/m2/day everyday from -3 to -2). Regarding the GVHD prophylaxis, patients in group 1 (n=17)
received CsA 1 mg/kg intravenously starting on day -7 and 2/mg/Kg from day -1 plus
alemtuzumab administered at a dose of 20 mg IV on -8 to -4 whereas in group 2 (n=23) pts
received CsA at same doses as group 1 plus MTX given at a dose of 15 mg/m2 intravenously on
days 1 and 10 mg/m2 on days 3, 6 and 11, followed by folinic acid rescue (15 mg in +1 and 10
mg in +3, +6 and +11 intravenously every 6 hours for 4 doses starting 24 hours after each
dose of MTX).
Acute and chronic GVHD were similarly graded by established criteria [20, 21]. In patients
receiving alemtuzumab, CsA was suspended by day +130. They also received donor lymphocyte
infusion (DLI) at a dose of 1 x 107 cluster of differentiation 3 / kg on day +180 in case of
active disease, persistence of minimal residual disease detected by flow cytometry or mixed
chimerism and no GVHD. In case mixed chimerism, donor lymphocyte infusion was performed if
patient hematopoiesis progressively increased. In patients receiving CsA + MTX, CsA was
suspended by day +180. These patients received DLI only in situations specified above.
The statistical analysis has been designed to identify a 20% difference in terms of
disease-free survival (based on the increased incidence of relapse in patients receiving
T-cell depletion).
| Status | Terminated |
| Enrollment | 72 |
| Est. completion date | November 2009 |
| Est. primary completion date | November 2009 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 45 Years to 65 Years |
| Eligibility |
Inclusion criteria: 1. Having an identical Human Leukocyte Antigens (HLA) or a mismatched family donor. 2. Age between 45 and 65 years (outside this age range at the discretion of each center). 3. Indications: - Follicular lymphoma with one of the following characteristics: 1. Poor prognosis follicular NHL (3 or more factors by Federico et al: erythrocyte sedimentation rate (ESR)> 30, male,> 60 years, high LDH> 2 extranodal areas, pathologic stage (PS) >2 or The International Prognostic Index (IPI) 3 or high lactate dehydrogenase (LDH) or micro Beta 2) failing to achieve CR with regimens including fludarabine and anti CD20 (cluster of differentiation antigen 20 ). 2. 2nd CR (complete response) or PR (partial response) not candidates for autologous transplantation; 3. persistent disease or relapse after autologous transplantation. - Other low-grade lymphomas: 1. relapsed after autologous transplantation. 2. autologous transplant candidates which can not be performed because of the inability to collect a sufficient number of cells, steam cells disease persistence, etc.. - Chronic lymphocytic leukemia with one of the following characteristics: 1. "B" symptoms: weight loss >10% in the last 6 months, fever >38ºC (degrees centigrade) for 14 days without infection, night sweats without infection 2. lymphadenopathy >10 cm or progressive, progressive splenomegaly 3. Anemia and/or thrombocytopenia secondary to bone marrow infiltration 4. Diffuse lymphocytic infiltration of the bone marrow 5. Progressive lymphocytosis (>50% in 2 months) or a lymphocyte doubling time <12 months Any of the above criteria is an inclusion criteria in the protocol in patients who have received at least one line of treatment including fludarabine 6. Patients with poor prognostic cytogenetic abnormalities: 17p-, 11q-with VDJ unmutated 4. Patients must also meet the following general requirements: 1. Performance status <3 (Zubrod score, Eastern Cooperative Oncology Group (ECOG) performance status or WHO (World Health Organization) ) 2. forced expiratory volume at one second (FEV1) > 39%, lung diffusing capacity for carbon monoxide (DLCO) and forced vital capacity (FVC) > 39% of the theoretical values 3. Total bilirubin and transaminases <3 x the normal maximum value, unless attributable to base haemopathy 4. Creatinine <2 x normal maximum and clearance> 40 mL / min unless attributable to his base haemopathy 5. No evidence of symptomatic disease, cirrhosis or active hepatitis 6. Negative serology for HIV 7. Written informed consent Exclusion criteria: 1. Impaired hepatic or renal function superior to that described above 2. Presence of serious diseases that prevent chemotherapy treatments 3. Presence of psychiatric comorbidity 4. HIV infection 5. Other prior neoplasm 6. Do not have signed informed consent 7. Pregnant or at risk of pregnancy by inadequate contraceptive measures. 8. Patients diagnosed with chronic lymphocytic leukemia (CLL) transformation to more aggressive cytologic or histologic forms (prolymphocytic leukemia, large cell lymphoma, Hodgkin's disease) and those affected with autoimmune hemolytic anemia |
| Country | Name | City | State |
|---|---|---|---|
| Poland | Department of Propedeutic Oncology, Medical University of Gdansk | Gdansk | |
| Spain | Clinical Hematology Department. ICO-Hospital Germans Trias i Pujol. Jose Carreras Research Institute | Badalona | Barcelona |
| Spain | Hospital Clinic I Provincial | Barcelona | |
| Spain | Santa Creu I Sant Pau Hospital | Barcelona | |
| Spain | Hospital Universitario de Salamanca | Salamanca |
| Lead Sponsor | Collaborator |
|---|---|
| Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea |
Poland, Spain,
Chakrabarti S, Mackinnon S, Chopra R, Kottaridis PD, Peggs K, O'Gorman P, Chakraverty R, Marshall T, Osman H, Mahendra P, Craddock C, Waldmann H, Hale G, Fegan CD, Yong K, Goldstone AH, Linch DC, Milligan DW. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood. 2002 Jun 15;99(12):4357-63. — View Citation
Chen PM, Tzeng CH, Fan FS, Hsieh RK, Wei CH. Bone marrow transplantation in Taiwan: low incidence of acute GVHD in patients with hematologic malignancies and severe aplastic anemia. Bone Marrow Transplant. 1994 Jun;13(6):709-11. — View Citation
Delgado J, Pillai S, Benjamin R, Caballero D, Martino R, Nathwani A, Lovell R, Thomson K, Perez-Simon JA, Sureda A, Kottaridis P, Vazquez L, Peggs K, Sierra J, Milligan D, Mackinnon S. The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia. Biol Blood Marrow Transplant. 2008 Nov;14(11):1288-97. doi: 10.1016/j.bbmt.2008.09.001. — View Citation
Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C, Claxton D, Donato M, Bruton J, Cohen A, Davis M, Andersson BS, Anderlini P, Gajewski J, Kornblau S, Andreeff M, Przepiorka D, Ueno NT, Molldrem J, Champlin R. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 2001 Feb 1;97(3):631-7. — View Citation
Hale G, Cobbold S, Novitzky N, Bunjes D, Willemze R, Prentice HG, Milligan D, MacKinnon S, Waldmann H; CAMPATH Users. CAMPATH-1 antibodies in stem-cell transplantation. Cytotherapy. 2001;3(3):145-64. — View Citation
Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J, Albitar M, Brettman L, Santabarbara P, Wacker B, Rai KR. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002 May 15;99(10):3554-61. — View Citation
Khouri IF, Keating M, Körbling M, Przepiorka D, Anderlini P, O'Brien S, Giralt S, Ippoliti C, von Wolff B, Gajewski J, Donato M, Claxton D, Ueno N, Andersson B, Gee A, Champlin R. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol. 1998 Aug;16(8):2817-24. — View Citation
Khouri IF, Przepiorka D, van Besien K, O'Brien S, Palmer JL, Lerner S, Mehra RC, Vriesendorp HM, Andersson BS, Giralt S, Körbling M, Keating MJ, Champlin RE. Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease. Br J Haematol. 1997 May;97(2):466-73. — View Citation
Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S, Peggs K, Verfuerth S, Pettengell R, Marsh JC, Schey S, Mahendra P, Morgan GJ, Hale G, Waldmann H, de Elvira MC, Williams CD, Devereux S, Linch DC, Goldstone AH, Mackinnon S. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood. 2000 Oct 1;96(7):2419-25. — View Citation
Kröger N, Shaw B, Iacobelli S, Zabelina T, Peggs K, Shimoni A, Nagler A, Binder T, Eiermann T, Madrigal A, Schwerdtfeger R, Kiehl M, Sayer HG, Beyer J, Bornhäuser M, Ayuk F, Zander AR, Marks DI; Clinical Trial Committee of the British Society of Blood and Marrow Transplantation and the German Cooperative Transplant Group. Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma. Br J Haematol. 2005 Jun;129(5):631-43. — View Citation
Martino R, Caballero MD, Canals C, Simón JA, Solano C, Urbano-Ispízua A, Bargay J, Rayón C, Léon A, Sarrá J, Odriozola J, Conde JG, Sierra J, San Miguel J; ALLOPBSCT Subcommittee of the Spanish Group for Haematopoietic Transplantation (GETH); Group GEL-TAMO. Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicentre study. Br J Haematol. 2001 Dec;115(3):653-9. — View Citation
Morris E, Thomson K, Craddock C, Mahendra P, Milligan D, Cook G, Smith GM, Parker A, Schey S, Chopra R, Hatton C, Tighe J, Hunter A, Peggs K, Linch D, Goldstone A, Mackinnon S. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood. 2004 Dec 15;104(13):3865-71. Epub 2004 Aug 10. — View Citation
Osterborg A, Dyer MJ, Bunjes D, Pangalis GA, Bastion Y, Catovsky D, Mellstedt H. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol. 1997 Apr;15(4):1567-74. — View Citation
Pérez-Simón JA, Kottaridis PD, Martino R, Craddock C, Caballero D, Chopra R, García-Conde J, Milligan DW, Schey S, Urbano-Ispizua A, Parker A, Leon A, Yong K, Sureda A, Hunter A, Sierra J, Goldstone AH, Linch DC, San Miguel JF, Mackinnon S; Spanish and United Kingdom Collaborative Groups for Nonmyeloablative Transplantation. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood. 2002 Nov 1;100(9):3121-7. — View Citation
Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995 Jun;15(6):825-8. Review. — View Citation
Rai KR, Freter CE, Mercier RJ, Cooper MR, Mitchell BS, Stadtmauer EA, Santábarbara P, Wacker B, Brettman L. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol. 2002 Sep 15;20(18):3891-7. — View Citation
Rondón G, Giralt S, Huh Y, Khouri I, Andersson B, Andreeff M, Champlin R. Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplant. 1996 Sep;18(3):669-72. — View Citation
Schweighofer CD, Ritgen M, Eichhorst BF, Busch R, Abenhardt W, Kneba M, Hallek M, Wendtner CM. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). Br J Haematol. 2009 Jan;144(1):95-8. doi: 10.1111/j.1365-2141.2008.07394.x. Epub 2008 Oct 30. — View Citation
Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Amar A, Brautbar C, Ben-Tal O, Eldor A, Or R. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998 Feb 1;91(3):756-63. — View Citation
Sullivan KM, Shulman HM, Storb R, Weiden PL, Witherspoon RP, McDonald GB, Schubert MM, Atkinson K, Thomas ED. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood. 1981 Feb;57(2):267-76. — View Citation
van Besien K, Sobocinski KA, Rowlings PA, Murphy SC, Armitage JO, Bishop MR, Chaekal OK, Gale RP, Klein JP, Lazarus HM, McCarthy PL Jr, Raemaekers JM, Reiffers J, Phillips GL, Schattenberg AV, Verdonck LF, Vose JM, Horowitz MM. Allogeneic bone marrow transplantation for low-grade lymphoma. Blood. 1998 Sep 1;92(5):1832-6. — View Citation
* Note: There are 21 references in all — Click here to view all references
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Other | incidence of graft versus host disease | Analyze the impact on the incidence of graft versus host disease (GVHD) acute and chronic CAMPATH-1H + DLI compared with MTX as GVHD prophylaxis in allogeneic related donor with nonmyeloablative conditioning. | 5 years | |
| Primary | Efficacy of transplantation in terms of event-free survival | To compare the efficacy of transplantation in terms of event-free survival between patients receiving CAMPATH-1H or methotrexate in allogeneic related donor with nonmyeloablative conditioning. | From +270 days | |
| Secondary | Incidence of infections and transplant-related mortality | Compare the incidence of infections and transplant-related mortality between the two arms | 1 year |